Regulatory News has published 1 story about Traferox Technologies on 23 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 23 September 2026.
This page is generated from Regulatory News’ editorial coverage of Traferox Technologies. It is not an advertisement.
On the record
- Company
- Traferox Technologies Inc.
- Headquarters
- Mississauga, Ontario, Canada
- Founded
- 2021, as a spin-out of University Health Network’s Toronto General Hospital transplant program
- Regulator
- U.S. Food and Drug Administration (CDRH)
- Latest milestone
- FDA 510(k) clearance, X°Port Heart Preservation System
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
